GLP1R and diabetes mellitus: Furthermore, findings from the Look AHEAD (Action for Health in Diabetes) study revealed socioeconomically independent racial/ethnic disparities in the initiation of emerging classes of diabetes medications in the United States, such as DPP-4 and SGLT-2 inhibitors and GLP-1 receptor agonists.